Premom: Pregnancy Remote Monitoring
Premom
1 other identifier
observational
60
0 countries
N/A
Brief Summary
Multiple cardiovascular adaptations happen during pregnancy. When gestational hypertensive disorders (GHD) occurs, these adaptations are abnormal. Approximately 5 - 8 % of all pregnant women develop GHD. GHD is an pregnancy complication which is characterized by an elevated blood pressure (≥ 140/90 mm Hg) and sometimes the appearance of proteinuria (≥3 g/ 24 hours) after twenty weeks of pregnancy. When this remains uncured, GHD can have severe complications for both mother and child. For this reason, a close follow-up of women with a high risk for developing this condition is recommended. This to detect and threat GHD early. Patients can be included when they are at least 10 weeks pregnant. Every pregnant women receives two devices to control daily here parameters in her home environment: a blood pressure monitor and an activity tracker. The women will be asked to perform two blood pressure measurements a day and to wear the activity tracker day and night. This data will be send by Bluetooth and Wi-Fi to the investigator in the hospital. Also will the women be asked to measure once a week her weight and send this to the hospital. Name of the device Measurement Protocol Blood pressure monitor Blood pressure, heart rate Twice a day (morning and evening) Activity tracker Activity- and sleep pattern Day and night Weight scale (not remote) Weight Once a week (morning) The investigator controls daily the incoming measurements and consults the responsible gyneacologist when events (= abnormal blood pressure or weight measurement) occurs. Depending on the decisions of the gyneacologist, following actions can be performed:
- Further observations
- Extra monitor
- Adjustments to the medication scheme
- Performing an 24 hours urine collection
- Admission to the prenatal observation ward When results are missing, the investigator contacts the women to ask of this measurement is due to personal or technical causes. The purpose of this study part is to detect early signs of PE. When patients gave birth, the data about the delivery (duration of labour, complications, mode of delivery, date of delivery, complications, parameters of the mother, specialties) and the neonate (gestational age, date and hour of birth, Apgar score, birth weight, length, complications and admission to the neonatal intensive care) will be collected. These data will be compared to the data of women who were admitted to the hospital for GHD, but who doesn't receive remote monitoring devices.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2015
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2015
CompletedFirst Submitted
Initial submission to the registry
February 27, 2017
CompletedFirst Posted
Study publicly available on registry
August 11, 2017
CompletedAugust 11, 2017
August 1, 2017
11 months
February 27, 2017
August 8, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
prenatal follow-up
total number of prenatal appointments, monitors, echo's, prenatal hospitalizations, hospitalizations until delivery
up to 9 months (delivery)
Secondary Outcomes (5)
maternal hemodynamic outcomes
Day of delivery
birth weight
Day of delivery
birth length
Day of delivery
Apgar at 1' and 5'
Day of delivery
admission to Neonatal Intensive Care
Day of delivery
Study Arms (1)
pregnant women
Interventions
Eligibility Criteria
pregnant women
You may qualify if:
- \> 10 weeks of gestation, in the possession of a Smartphone
You may not qualify if:
- congenital malformations of the fetus
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hasselt Universitylead
- Ziekenhuis Oost-Limburgcollaborator
Related Publications (2)
Lanssens D, Vandenberk T, Storms V, Thijs I, Grieten L, Bamelis L, Gyselaers W, Tang E, Luyten P. Changes in Intrapersonal Factors of Participants in the Pregnancy Remote Monitoring Study Who Are at Risk for Pregnancy-Induced Hypertension: Descriptive Quantitative Study. J Med Internet Res. 2023 Sep 6;25:e42686. doi: 10.2196/42686.
PMID: 37672324DERIVEDLanssens D, Vandenberk T, Lodewijckx J, Peeters T, Storms V, Thijs IM, Grieten L, Gyselaers W. Midwives', Obstetricians', and Recently Delivered Mothers' Perceptions of Remote Monitoring for Prenatal Care: Retrospective Survey. J Med Internet Res. 2019 Apr 15;21(4):e10887. doi: 10.2196/10887.
PMID: 30985286DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Wilfried Gyselaers, prof. dr.
Hasselt University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- prof. dr.
Study Record Dates
First Submitted
February 27, 2017
First Posted
August 11, 2017
Study Start
January 1, 2015
Primary Completion
December 1, 2015
Study Completion
December 1, 2015
Last Updated
August 11, 2017
Record last verified: 2017-08